Lineage Cell Therapeutics

All of us at $LCTX and CCN wish to express our gratitude to those who inspire us as #WeWorktoRestore - function, dignity, strength, clarity, independence, and hope. @CEO_Culley #CellTherapy #ReplaceAndRestore #Careers

$LCTX

$LCTX reported fourth quarter and full year 2025 financial results and will host a conference call at 4:30 pm ET / 1:30 pm PT today to provide a business update. Learn more: bit.ly/4dazDDA #ReplaceAndRestore

$LCTX will report 4Q and full year 2025 financial results on Thursday, March 5, 2026, and host a conference call at 4:30 pm ET / 1:30 pm PT to provide a business update. Learn more: bit.ly/4ufcw19 #ReplaceAndRestore

$LCTX has activated a second DOSED clinical study site for #OPC1, its allogeneic cell transplant therapy candidate for spinal cord injury, at @RanchoResearchI, in conjunction with their affiliated hospital, @RanchoRehab, where Charles Liu, M.D., Ph.D., will serve as Principal Investigator. For more about Rancho Research Institute, please visit: bit.ly/4qXSrKo For more about Rancho Los Amigos National Rehabilitation Center, please visit: bit.ly/4gmHBsI For more about DOSED, please visit: bit.ly/45QJ0Ei #ReplaceandRestore #ClinicalTrials #SCI #SpinalCordInjury

.@CEO_Culley of $LCTX spoke with @pharmaphorum reporter @JonahComstock about why allogeneic, off-the-shelf cell therapy still has a path beyond oncology, plus long-term tolerability data and what Lineage plans to share about its cell programs in 2026. For more: bit.ly/4tgBFrq #CellTherapy #RegenerativeMedicine #Biotech

$LCTX #OpRegen #dryAMD

Rami Skaliter, CEO of Cell Cure Neurosciences, a $LCTX subsidiary, is presenting at @HansonWade’s 4th Annual Ophthalmic Drug Delivery Summit in San Francisco, hosting a workshop session on overcoming clinical applicability challenges in cell therapy for vision and beyond. For more about the conference: bit.ly/3M6vk1a #Ophthalmology #DrugDelivery #CellTherapy

.@CEO_Culley of $LCTX joined @Fraiser_K, the host of The Top Line podcast from @FiercePharma, for a conversation about investor sentiment and why manufacturing planning needs to start earlier than most teams think. Listen here: bit.ly/4qk1UeT #Biotech #CellTherapy #Manufacturing #HealthcareInnovation

.@CEO_Culley and the $LCTX business development team are in San Francisco for JPMorgan Healthcare Conference Week, where we’re looking forward to key investor, partnering, and biotech discussions. #ReplaceAndRestore #RegenerativeMedicine #JPM2026

$LCTX thanks @FiercePharma’s @Fraiser_K for the roundtable on what could shape 2026. Lineage @CEO_Culley shares why Lineage remains authentically optimistic, and why manufacturing matters, especially for complex, off-the-shelf cell therapies where CMC decisions can shape the path to scale and consistency. Read the full article: bit.ly/4jF2KjN #CellTherapy #RegenerativeMedicine #CMC #Manufacturing #Biotech

$LCTX has received a novel iPSC cell line genetically engineered to be hypoimmune from @FactorBio, which Lineage can use for differentiation into certain cell transplant product candidates. Lineage plans to evaluate the line for the ability to adapt to its proprietary cell expansion manufacturing platform, AlloSCOPE™ (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering). For more: bit.ly/4pwT4Jv #ReplaceandRestore #CellTherapy #iPSC #RegenerativeMedicine

$LCTX ‘s @CEO_Culley has published a letter to stockholders, outlining the company’s 2025 progress and providing a corporate outlook for 2026. Read the full letter: bit.ly/4sm9N53 #ReplaceandRestore #RegenerativeMedicine #Neurology #Ophthalmology #Type1Diabetes #HearingLoss

We’d like to thank Max Brennan for interviewing $LCTX ‘s CFO Jill Howe on The BioHub Podcast. In the episode, Jill shares how Lineage’s allogeneic cell therapy platform is advancing programs in dry AMD, spinal cord injury, hearing loss, and type 1 diabetes. Listen on Apple Podcasts: podcasts.apple.com/us/podcast/epi… Watch on YouTube: youtube.com/watch?v=2erqRy… #CFOLeadership #FinanceFunction #ReplaceAndRestore

$LCTX extends its thanks to @btigresearch’s Julian Harrison for hosting a fireside chat with @CEO_Culley during the 5th Annual BTIG #Ophthalmology Day. #ReplaceAndRestore #RegenerativeMedicine #InvestorRelations

On the ground at #OISXV in San Diego, $LCTX @CEO_Culley joined the panel “The Future Outlook of Dry AMD: One Disease or Many?” Thanks to moderator Emmett T. Cunningham Jr., MD, PhD, MPH, and @OISTWEETS for hosting a thoughtful discussion on dry AMD.

$LCTX announces achievement of the first milestone under its worldwide collaboration with @Roche and @Genentech for OpRegen® (RG6501), an allogeneic RPE cell therapy in development for geographic atrophy (GA) secondary to age-related macular degeneration #AMD. Milestone achieved based on manufacturing and clinical advancements related to the OpRegen cell therapy program. Learn more: bit.ly/48v9iNU #ReplaceAndRestore #GeographicAtrophy #DryAMD | @CEO_Culley

$LCTX @CEO_Culley will join the #OISXV panel “The Future Outlook of Dry AMD: One Disease or Many?” in San Diego, at OIS XV produced by @OISTWEETS, on November 22, from 12:05–12:40 PM. ois.net/ophthalmology-… #ReplaceAndRestore #RegenerativeMedicine #DryAMD

Thank you @WeekinHearing for hosting $LCTX ’s @CEO_Culley to discuss our collaboration on ReSonance (ANP1), an auditory neuronal cell transplant for hearing loss that aims to replace damaged auditory neurons and is supported by up to $12 million in research funding. Watch on YouTube: bit.ly/43FNfkW Read the transcript: bit.ly/48anLO9 #CellTherapy #HearingLoss #RegenerativeMedicine

.@CTS_Tahoe 2025 Summit has published a recording of the 36-month results from the OpRegen® (RG6501) Phase 1/2a clinical study in patients with geographic atrophy (GA) secondary to AMD. To watch, please visit the link below and view the third to last video, “First Time Results of Clinical Trials” starting at 24:51: ctsretina.org/cts-2025-recor… #CTS2025 #CTSRetina @ArshadKhanani @Genentecheye $LCTX @CEO_Culley

Why did we spend so many years investing in manufacturing? Because it doesn’t matter if you’re winning at halfway. Terrific article! $LCTX cellandgene.com/doc/why-do-so-…